Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment 2022-06-10 19:00
Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350 2022-06-10 18:42
J INTS BIO successfully held two Korean Advisory Board Meetings for its Novel Oral 4th Generation EGFR TKI (JIN-A02) 2022-06-10 17:00
Inteleos Announces Maya Health Alliance as MissionPOCUS Selection for 2022 2022-06-09 22:09
BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer's disease and drug delivery system technology at the 2022 BIO International Convention 2022-06-09 20:30
Standigm Signs MOU with Merck Korea for AI drug Discovery Research 2022-06-09 14:46
Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board 2022-06-09 00:05
OnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug Conjugate 2022-06-08 20:00
Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody 2022-06-08 18:11
ASCO 2022 | Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC 2022-06-08 08:00
ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL 2022-06-08 08:00
The 3rd BIO International Convention 2022 is Approaching 2022-06-07 19:23
PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT 2022-06-07 19:00
Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting 2022-06-07 14:00
ASCO 2022 | Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors who Progressed on Immunotherapies 2022-06-07 11:30
ASCO 2022 | The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83.3% 2022-06-07 11:28
iNtRON Completes GLP-TOX Studies of BAL200 2022-06-07 09:00
MGI Announces Commercial Availability of DNBSEQ™ Sequencers* in the United States 2022-06-07 00:59
IND approval from the US FDA for Phase II SAR-Bombesin imaging trial in prostate cancer 2022-06-06 21:08
Senhwa's Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC 2022-06-06 21:00
1 124 125 126 127 128 432